Daniela Semedo, PhD,  —

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Articles by Daniela Semedo

X-Chem, Vertex to Jointly Develop Small Molecules for CF, Other Severe Genetic Diseases

X-Chem Pharmaceuticals and Vertex Pharmaceuticals will jointly develop small molecules targeting cystic fibrosis (CF) and other severe genetic diseases. Under the collaboration announced May 16, X-Chem will apply its proprietary DEX libraries — which holds more than 120 billion small compounds — to discover new drug candidates against targets involved in CF…

Dalton, Arch Plan Joint Production of AB569 for Clinical Trials Involving Treatment-resistant Lung Infections

Dalton and Arch Biopartners are partnering to manufacture AB569 for clinical trials involving cystic fibrosis (CF) patients with chronic, antibiotic-resistant bacterial lung infections. Under the agreement, the two will divide manufacturing tasks, including formulating the compound, putting it in containers safely, and doing quality-control testing. The drug will be…

AeroVanc Inhaled Powder for Cystic Fibrosis Infections Receives US and Canadian Patents

Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant lung infections in cystic fibrosis (CF) patients. AeroVanc addresses the growing challenge of the methicillin-resistant Staphylococcus aureus (MRSA) bacteria, Savara said in a press release. The patents from the United States Patent and Trademark…

15 Non-profits in 7 Countries Win Vertex Grants for Cystic Fibrosis Projects

Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year, the program’s sponsor, Vertex Pharmaceuticals, announced. The grants, now in their third year, go to medical, academic, patient, and community organizations serving the cystic fibrosis (CF) community. Since the program started in…

Enterprise Therapeutics Gets Cystic Fibrosis Trust Grant to Develop Innovative Treatments

Enterprise Therapeutics has received a £95,000 grant from Britain’s Cystic Fibrosis Trust to develop innovative treatments for cystic fibrosis (CF). The money, equivalent to $118,000, will support the development of CF therapies based on Enterprise Therapeutics’ bronchosphere technology platform. Cystic fibrosis blocks airway passages. The condition stems from faulty airway-surface…

Corbus Therapy Anabasum Reduces Acute Pulmonary Exacerbations by Up to 75% in CF Patients

Corbus Pharmaceuticals recently reported that its Phase 2 clinical trial examining multiple doses of anabasum (formerly known as JBT-101 or Resunab) compared to placebo in patients with cystic fibrosis (CF) achieved the trial’s primary endpoint demonstrating an acceptable safety and tolerability profile at all doses, with no serious or severe adverse…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.